FINGOLIMOD HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for fingolimod hydrochloride and what is the scope of patent protection?
Fingolimod hydrochloride
is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Ltd, Bionpharma, Chartwell Rx, Dr Reddys, Ezra Ventures, Glenmark Pharms Ltd, Hec Pharm Co Ltd, Hetero Labs Ltd V, Mylan, Prinston Inc, Sun Pharm, Teva Pharms Usa, Zydus Pharms, and Novartis, and is included in nineteen NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Fingolimod hydrochloride has two hundred and forty-six patent family members in fifty countries.
There are twenty drug master file entries for fingolimod hydrochloride. Nineteen suppliers are listed for this compound.
Summary for FINGOLIMOD HYDROCHLORIDE
International Patents: | 246 |
US Patents: | 4 |
Tradenames: | 2 |
Applicants: | 18 |
NDAs: | 19 |
Drug Master File Entries: | 20 |
Finished Product Suppliers / Packagers: | 19 |
Raw Ingredient (Bulk) Api Vendors: | 139 |
Clinical Trials: | 74 |
Patent Applications: | 829 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FINGOLIMOD HYDROCHLORIDE |
What excipients (inactive ingredients) are in FINGOLIMOD HYDROCHLORIDE? | FINGOLIMOD HYDROCHLORIDE excipients list |
DailyMed Link: | FINGOLIMOD HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for FINGOLIMOD HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Methodist Hospital Research Institute | Phase 2 |
General Hospital of Shenyang Military Region | Phase 4 |
Hoffmann-La Roche | Phase 3 |
Pharmacology for FINGOLIMOD HYDROCHLORIDE
Drug Class | Sphingosine 1-phosphate Receptor Modulator |
Mechanism of Action | Sphingosine 1-Phosphate Receptor Modulators |
Medical Subject Heading (MeSH) Categories for FINGOLIMOD HYDROCHLORIDE
Paragraph IV (Patent) Challenges for FINGOLIMOD HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
GILENYA | Capsules | fingolimod hydrochloride | 0.25 mg | 022527 | 1 | 2018-07-19 |
GILENYA | Capsules | fingolimod hydrochloride | 0.5 mg | 022527 | 19 | 2014-09-22 |
US Patents and Regulatory Information for FINGOLIMOD HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Pharms Ltd | FINGOLIMOD HYDROCHLORIDE | fingolimod hydrochloride | CAPSULE;ORAL | 207985-001 | Jun 18, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Apotex | FINGOLIMOD HYDROCHLORIDE | fingolimod hydrochloride | CAPSULE;ORAL | 207993-001 | Dec 18, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527-002 | May 11, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FINGOLIMOD HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527-001 | Sep 21, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527-002 | May 11, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527-001 | Sep 21, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FINGOLIMOD HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2012148593 | ПРЕДНАЗНАЧЕННАЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | ⤷ Try a Trial |
European Patent Office | 2959894 | MODULATEURS DU RÉCEPTEUR S1P POUR TRAITER LA SCLÉROSE EN PLAQUES (S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS) | ⤷ Try a Trial |
Mexico | PA05010860 | COMPOSICIONES SOLIDAS FARMACEUTICAS QUE COMPRENDEN UN AGONISTA DE RECEPTOR SIP Y Y UN ALCOHOL DE AZUCAR. (ORGANIC COMPOUNDS.) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FINGOLIMOD HYDROCHLORIDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613288 | 91867 | Luxembourg | ⤷ Try a Trial | 91867, EXPIRES: 20260317 |
0627406 | 11C0021 | France | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES EN PARTICULIER SON CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/11/677/001 20110317 |
1613288 | 28/2011 | Austria | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMODHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/677-001-004 20110317 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.